Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
A triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) originally developed for Parkinson's and Alzheimer's that showed remarkable weight loss in Phase 2 trials. Now being developed specifically for obesity.
A dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Represents the next generation of incretin-based therapies with potentially superior efficacy to semaglutide for weight loss.
Inhibits reuptake of serotonin, norepinephrine, and dopamine, reducing appetite and increasing energy expenditure through central nervous system modulation. Different mechanism than GLP-1 agonists.
Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, producing enhanced insulin secretion, appetite suppression, and metabolic improvements beyond what single-agonist drugs achieve.
- Weight management (investigational)
- Appetite suppression
- Metabolic rate enhancement
- Weight management
- Type 2 diabetes treatment
- Metabolic health improvement
- Increased heart rate
- Dry mouth
- Insomnia
- Constipation
- Potential cardiovascular concerns
- Not yet approved — full safety profile unknown
- GI side effects (nausea, diarrhea, vomiting)
- Pancreatitis risk
- Injection site reactions
- Potential thyroid concerns
Phase 3 clinical trials ongoing. Phase 2 showed up to 12.8% body weight loss at 24 weeks. Approved in Mexico (2024). Not FDA-approved in the US.
FDA-approved as Mounjaro (diabetes, 2022) and Zepbound (weight management, 2023).
- Tesofensine for treatment of obesity
2008 · PubMed
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.